Pepticom’s New Spinout Company, PeptiCov, to Focus on COVID-19
Pepticom, a leader in artificial intelligence peptide drug design and discovery, announced today that it has raised $2.6 million to establish a company to focus
BrainsWay Ltd. Closes $45.2 Million Underwritten Public Offering of American Depositary Share
BrainsWay Ltd. (NASDAQ & TASE: BWAY) a global leader in the advanced noninvasive treatment of brain disorders, closed its previously announced underwritten public offering of
Sanseera’s Blood Test Could Replace Cancer Biopsies
Hebrew University of Jerusalem researchers Dr. Ronen Sadeh and Prof. Nir Friedman have develop a simple blood test (liquid biopsy) that they say could replace
Gamida Cell Raises $75 Million Financing with Highbridge Capital Management
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to developing and commercializing cures for blood cancers and serious hematologic diseases, today announced
Brainwatch Tracks Coma Patients’ Condition With Goggles That Monitor Pupils
BrainWatch Tech is working on prototype of device that will automatically measure and record pupillary reactions to light in patients with severe brain injury. The
Future Meat Technologies Reduces Cost of Cultured Chicken Breast Below $10/ Kg
Future Meat Technologies, an Israel-based company developing innovative technology to produce cultured meat, beat market expectations by reducing the production cost of a cultured chicken
BrainQ gets FDA Breakthrough Status for its Device for Reducing Stroke Disability
BrainQ, the Israeli start-up with a therapeutic solution to reduce disability following stroke, announced today that the United States Food and Drug Administration (FDA) has
AID Invests $200m in Jerusalem RNA Vaccine Plant
AID Genomics has already set up a laboratory for Covid-19 testing in Jerusalem, after winning the Israel concession for testing from Chinese company BGI. Kelvin
Omnix Medical Wins €10.8M in EIC Accelerator Funding
OmnixMedical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has been awarded €10.8 million in EU funding under the EIC
